Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Mortality Rate in Type 2 Myocardial Infarction: Observations from an Unselected Hospital Cohort Lotte Saaby, MD, Tina Svenstrup Poulsen, MD, PhD, Axel.

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Pierre Loulergue, MD, MSc, Agnès Guerre, MD

Sexuality The American Journal of Medicine

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

An Unusual Cause of Leg Ulcerations

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Characteristics of Hospitalized Patients with Atrial Fibrillation in Taiwan: A Nationwide Observation Cheng-Han Lee, MD, Ping-Yen Liu, MD, PhD, Liang-Miin.

Volume 137, Issue 2, Pages (February 2010)

Pierre Loulergue, MD, MSc, Agnès Guerre, MD

Scientific and Organizational Collaboration in Comparative Effectiveness Research: The VA Cooperative Studies Program Model Grant D. Huang, MPH, PhD,

Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial Yutao Guo,

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Sayed H. Naderi, BMedSci, Jonathan P. Bestwick, MSc, David S. Wald, MD

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

‘Real-World’ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey Gregory Y.H. Lip, MD, Cécile Laroche, MSc, Gheorghe-Andrei Dan,

Thomas E. MacMillan, MD, MSc, Terence Tang, MD, Rodrigo B

Epidemiology of Myelodysplastic Syndromes

Trend in Mortality after Stroke with Atrial Fibrillation

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

Pulmonary Embolism with Right Ventricular Dysfunction: Who Should Receive Thrombolytic Agents? Hem Desai, MD, MPH, Bhupinder Natt, MD, Christian Bime,

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Artificial Hyperparathyroidism—Think Twice Before Taking Your Blood Sample Daniel Foehring, MD, Lars Moeller, MD, Dagmar Fuhrer, MD, Harald Lahner, MD

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

The Reply The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Carlos Aguilar, MD, Valentin del Villar, MD

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

When Guidelines Cause Hypertension

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

External Validation of the Simple NULL-PLEASE Clinical Score in Predicting Outcome of Out-of-Hospital Cardiac Arrest Tatjana S. Potpara, MD, PhD, Miroslav.

Does Methylphenidate Reduce the Symptoms of Chronic Fatigue Syndrome?

Disseminated Zoster After Trauma in an Immunocompetent Patient

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

MATCH Results: Implications for the Internist

Mortality Rate in Type 2 Myocardial Infarction: Observations from an Unselected Hospital Cohort Lotte Saaby, MD, Tina Svenstrup Poulsen, MD, PhD, Axel.

Sharan Prakash Sharma, MD, Karleung Siu, MD

To Reduce Stroke with PFO Closure, Respect the Shunt

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

John-Michael Gamble, BScPharm, MSc, Dean T. Eurich, PhD, Thomas J

Evaluation of Severe Infection and Survival After Splenectomy

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

National Trends in Ambulatory Oral Anticoagulant Use

A Post-cure Complication

The American Journal of Medicine

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Trends in Prolonged Hospitalizations in the United States from 2001 to 2012: A Longitudinal Cohort Study Lauren Doctoroff, MD, Douglas J. Hsu, MD, Kenneth.

The Association Between Barium Examination and Subsequent Appendicitis: A Nationwide Population-Based Study Hao-Ming Li, MD, Lee-Ren Yeh, MD, Ying-Kai.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Falls in Older Adults: Risk Assessment, Management and Prevention

Emily G. McDonald, MD, MSc, Ramy R. Saleh, MD, Todd C. Lee, MD, MPH

David Tian, MD, Ram Jhingan Mohan, MD, Gary Stallings, MD

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Presentation transcript:

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD, PhD, Lars Hvilsted Rasmussen, MD, PhD, Anders Gorst-Rasmussen, MSc, PhD, Flemming Skjøth, MSc, PhD, Deirdre A. Lane, PhD, Gregory Y.H. Lip, MD The American Journal of Medicine Volume 127, Issue 12, Pages 1172-1178.e5 (December 2014) DOI: 10.1016/j.amjmed.2014.07.023 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 Flow chart showing how the study population was obtained from prescription purchase data. Boxes show number of purchases with number of unique subjects in parentheses. The final study population with prior stroke is displayed in dashed boxes. In the vitamin K antagonist (VKA)-experienced stratum, warfarin purchasers were sampled in a 2:1 ratio for each switcher to dabigatran (according to calendar month of purchase and duration of VKA-experience). The American Journal of Medicine 2014 127, 1172-1178.e5DOI: (10.1016/j.amjmed.2014.07.023) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 2 Crude cumulative incidence of the composite endpoint of stroke or transient ischemic attack, according to Vitamin K antagonist-experience and current treatment. The American Journal of Medicine 2014 127, 1172-1178.e5DOI: (10.1016/j.amjmed.2014.07.023) Copyright © 2014 Elsevier Inc. Terms and Conditions